Global Drug-Device Combination Market Set To Grow To $184bn By 2021

13 August 2018
Pharma

Visiongain has launched a new pharma report Global Drug-Device Combination Market 2017-2027: Drug Eluting Stents, Photosensitizers, Orthopaedic Products, Infusion Pumps, Wound Care Products, Transmucosal Products, Transdermal Patches, Hospital & Clinics, Ambulatory Surgical Centres, Emergency Service Centres, Home Care Settings

Combination products are being increasingly used in patients suffering from chronic disorders such as cardiac disease, cancer, diabetes, and multiple sclerosis among others. Owing to these products, a new dynamic has been initiated in the medical product development, regulatory approval as well as corporate interaction. Over the last decade, various regulatory agencies have developed numerous competences and regulations due to the rising integration of drugs and devices occurring in the latest generation of combination products.

The lead analyst of the report commented “the Drug-Device combination market is driven by initiatives from governments and NGOs in support of drug delivery implants, a rise in the usage of minimally invasive surgeries, technological innovations and advancements, and increasing prevalence of chronic disorders. However, regulatory challenges pertaining to recall of products due to adverse effects, technical challenges related to drug delivery and higher cost of the products are some of the factors hampering the growth of the Drug-Device combination market.”

Leading companies featured in the report include Medtronic, Boston Scientific Corporation, Stryker Corporation, Ethicon Inc, C.R. Bard Inc., Medline Industries Inc., Mylan Inc., Terumo Corporation, Pinnacle Biologics Inc., and W. L. Gore & Associates, Inc.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongainglobal.com or call her on +44 (0) 207 336 6100

About visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Healthcare Cold Chain Logistics Market Report 2020-2030

. The growth of this market is majorly driven by increasing sales of temperature sensitive pharmaceutical products, longer life expectancy and rising geriatric population are some of the prominent factors.

16 September 2020

Read

Visiongain Publishes Vaccines Sales Market Report 2020-2030

Visiongain forecasts a continuing growth in global market, submarket and product sales as human vaccines drive pharmaceutical business sales. New key players and technological progress will enter the industry, leading to an increase in the market size of the world market for human vaccines in general.

14 September 2020

Read

Visiongain Publishes Ophthalmic Ultrasound Systems Market Report 2020-2030

The global ophthalmic ultrasound systems market is driven by factors such as the increasing prevalence of ocular disorders and diseases, adoption of novel ophthalmic technologies, rising focus on research & development, and growing health awareness amongst the population.

09 September 2020

Read

Visiongain Publishes Drug Discovery Outsourcing Market Report 2020-2030

The current COVID-19 pandemic is anticipated to have a minor impact on the overall outsourcing business outlook for global drug discovery. Also, significant growth during the COVID-19 pandemic is expected to be seen in the outsourcing of drugs and medicines needed to treat COVID-19 infections.

07 September 2020

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever